Haematological and Bone Marrow Cancers
Haematological cancers are cancers which affect the blood, bone marrow and lymph nodes. The most common types include leukaemias, lymphomas, myelomas and myeloproliferative disorders (MPDs). All affect cell types that are important for regulating the activity of the immune system.
Leukaemias start in blood-forming tissue such as the bone marrow and results in the release of large numbers of abnormal blood cells into the bloodstream. Leukaemias may be classed as acute or chronic and may stem from lymphocytic or myeloid cells. This equates to four subtypes; acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL), chronic myeloid leukaemia (CML) and chronic lymphocytic leukaemia (CLL).
Lymphomas impact on lymphocytes and presents as a solid tumour that generally develops in the lymph nodes, spleen, bone marrow or blood. There are two subtypes, Hodgkin lymphoma and non-Hodgkin’s lymphoma. Myelomas lead to an accumulation of plasma cells in bone marrow which impacts on the production of normal blood cells.
Related news and insights
GlaxoSmithKline plc announced the FDA has approved Blenrep (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory agent.
Pfizer announced that the European Commission approved Daurismo (glasdegib), a Hedgehog pathway inhibitor, in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly diagnosed (de novo or secondary) acute myeloid leukemia (AML) in adult patients who are not candidates for standard chemotherapy.
Detailed results from both the Phase II ACE-CL-001 trial and the pivotal Phase III ASCEND trial showed the long-term efficacy and tolerability of Calquence (acalabrutinib), from AstraZeneca, in chronic lymphocytic leukaemia (CLL), one of the most common types of adult leukaemia.
This guideline covers the planning and management of end of life and palliative care in for infants, children and young people (aged 0-17 years) with life-limiting conditions. It aims to involve children, young people and their families...
The estimated overall incidence of acute lymphoblastic leukaemia and lymphoblastic lymphoma in Europe is 1.28 per 1 000 000 individuals annually, with significant age-related variations.
You may be interested in...
ICRMB 2021: 15. International Conference on Reproductive Medicine and Biology aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Reproductive Medicine and Biology.
International Conference on Nephrology and Urology
ICNU 2021: 15. International Conference on Nephrology and Urology aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Nephrology and Urology.
18th Meeting of the EAU Section of Oncological Urology
ESOU21 will take place in conjunction with the meeting of the EAU Section of Urological Research (ESUR). Thus it will be an opportunity to have collaborative sessions and knowledge exchange with our colleagues from this prestigious office of the EAU.